Watchlist Price Alert

Esperion Therapeutics Inc... (ESPR)

NASDAQ: ESPR · Real-Time Price · USD

0.80

0.02 (2.93%)

At close: May 16, 2025, 3:59 PM

0.80

-0.12%

After-hours: May 16, 2025, 05:57 PM EDT

2.93% (1D)

Bid	0.8
Market Cap	158.56M
Revenue (ttm)	259.57M
Net Income (ttm)	-153.22M
EPS (ttm)	-0.85
PE Ratio (ttm)	-0.94
Forward PE	-3.7
Analyst	Buy

Ask	0.81
Volume	4,648,673
Avg. Volume (20D)	5,184,964
Open	0.80
Previous Close	0.78
Day's Range	0.75 - 0.80
52-Week Range	0.69 - 3.94
Beta	0.74

About ESPR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ESPR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ESPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Esperion Therapeutics has released their quartely earnings on May 6, 2025:

Revenue of $65M exceeds estimates by $10.8M, with -52.81% YoY decline.

EPS of -0.21 misses estimates by -0.06, with -161.76% YoY decline.

Why Price Moved

2 months ago

+12.03%

Esperion Therapeutics shares are trading higher af... Unlock content with Pro Subscription

5 months ago

+5.58%

Esperion Therapeutics shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $8.

News

1 week ago · zacks.com

ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year.

1 week ago · seekingalpha.com

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Ch...

1 week ago · zacks.com

Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.34 per share a year ago.

2 weeks ago · zacks.com

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · zacks.com

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.

3 weeks ago · zacks.com

Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Esperion Therapeutics (ESPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

1 month ago · zacks.com

ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia

Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.

2 months ago · zacks.com

ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates.

2 months ago · seekingalpha.com

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and ...

2 months ago · zacks.com

Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.50 per share a year ago.

Load More News